Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 115Breast Neoplasms 113Ovarian Neoplasms 71Triple Negative Breast Neoplasms 56Fallopian Tube Neoplasms 42Endometrial Neoplasms 42Squamous Cell Carcinoma of Head and Neck 39Lung Neoplasms 38Neoplasm Metastasis 35Stomach Neoplasms 28Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 27Esophageal Neoplasms 22Esophageal Squamous Cell Carcinoma 21Head and Neck Neoplasms 16Carcinoma 16Uterine Cervical Neoplasms 15Carcinoma, Ovarian Epithelial 15Colorectal Neoplasms 14Carcinoma, Squamous Cell 11Adenocarcinoma 10Small Cell Lung Carcinoma 9Adenocarcinoma Of Esophagus 9Peritoneal Neoplasms 8Oropharyngeal Neoplasms 8Melanoma 8Carcinoma, Transitional Cell 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Mouth Neoplasms 7

Interventions

Letrozole 2trametinib 1ribociclib 1niraparib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cystadenocarcinoma, Serous × Paclitaxel × 1 year × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡